Eli Lilly & CO Form 4 insider transactions

Eli Lilly & Co. Director J. Erik Fyrwald acquired 14.206 shares of common stock by deferring cash compensation under the company's director deferral plan.

Director Ralph Alvarez acquired 16.833 shares of Eli Lilly & Co common stock at $698.05 per share on August 18, 2025.

Eli Lilly's Executive Vice President and Chief Financial Officer, Lucas Montarce, acquired 715 shares of common stock in a pre-planned transaction.

Eli Lilly & Co. Director Ralph Alvarez acquired 758 shares of common stock at a price of $660.254 per share.

Eli Lilly's EVP and President of Lilly Oncology, Jacob Van Naarden, purchased 1,000 shares of company common stock for over $647,000 as part of a pre-planned transaction.

Eli Lilly & Co. Executive Vice President Ilya Yuffa sold 1,250 shares of common stock for $627.01 per share on August 11, 2025, as part of a pre-arranged trading plan.

Eli Lilly's President, Chair, and CEO, David A. Ricks, acquired 1,632 shares of company common stock for over $1 million.

Eli Lilly's EVP, CSO, and President of LRL & LLY Imm, Daniel Skovronsky, plans to purchase 1,000 shares of company common stock for approximately $634,405.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 117 shares of common stock at $641.182 per share, increasing her direct beneficial ownership.

Eli Lilly & Co. Director J. Erik Fyrwald acquired 1,565 shares of common stock for approximately $1 million.

Eli Lilly & Co. Director Jamere Jackson reported a planned acquisition of 200 common shares at $639.563 per share, effective August 8, 2025, under a 10b5-1 plan.

Eli Lilly and Company's EVP of Global Quality, Melissa Seymour, reported the acquisition and disposition of common stock and restricted stock units.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 280,000 shares of common stock for approximately $225.38 million.

Eli Lilly & Co. Director Juan R. Luciano acquired 19.462 shares of common stock at $762.18 per share on July 21, 2025, as deferred compensation.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired additional common stock through a deferred compensation arrangement, increasing her beneficial ownership.

Eli Lilly & Co. Director Mary Lynne Hedley acquired 13.011 shares of common stock through a deferred compensation plan, increasing her beneficial ownership.

Eli Lilly & Co. Director J. Erik Fyrwald acquired 13.011 shares of common stock valued at $762.18 per share, as part of a deferred compensation plan.

Eli Lilly & Co. Director Ralph Alvarez acquired 15.416 shares of common stock through a compensation deferral plan, aligning his interests with shareholders.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 6.14 shares of common stock at a price of $807.58 per share, as part of the company's Directors' Deferral Plan.

Eli Lilly & Co. Director Juan R. Luciano acquired 18.368 shares of common stock through a compensation deferral plan, increasing his beneficial ownership to 16,362.472 shares.

Eli Lilly & Co. Director Mary Lynne Hedley acquired 12.279 shares of common stock on June 16, 2025, as part of a deferred compensation plan, increasing her direct beneficial ownership.

Eli Lilly & Co. Director J. Erik Fyrwald acquired 12.279 shares of common stock at $807.58 per share, deferring them as stock units under the company's Directors' Deferral Plan.

Eli Lilly & Co. Director Ralph Alvarez acquired 14.55 shares of common stock on June 16, 2025, as part of a compensation deferral plan, increasing his total beneficial ownership to 54,979.164 shares.

Eli Lilly & Co's Senior Vice President of Finance and Chief Accounting Officer, Donald A. Zakrowski, sold 1,000 shares of common stock for $716.41 per share on May 27, 2025, as part of a pre-established 10b5-1 trading plan.

Director Gabrielle Sulzberger acquired 6.566 shares of Eli Lilly & Co common stock at $755.11 per share on May 19, 2025, through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired 19.644 shares of Eli Lilly & Co (LLY) common stock on May 19, 2025, through the Lilly Directors' Deferral Plan.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock through the company's Directors' Deferral Plan.

J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 13.133 shares of common stock under the company's Directors' Deferral Plan.

Director Ralph Alvarez acquired 15.561 shares of Eli Lilly & Co common stock under the company's Directors' Deferral Plan.

Ilya Yuffa, EVP & President, LLY International, sold 1,250 shares of Eli Lilly & Co. common stock at $749.24 per share on May 14, 2025, under a pre-arranged 10b5-1 trading plan.